Posts by Sandra Ansanay-Alex
AzureCell Therapies Secures Innosuisse Grant to Advance Parkinson Disease Treatment
AzureCell Therapies, a University of Geneva spinoff at the forefront of regenerative medicine, has been awarded a CHF 650,000 grant from Innosuisse, Switzerland’s innovation agency, to advance its pioneering cell-replacement therapies for Parkinson’s disease. Rooted in over 20 years of research from the University of Geneva and backed by over CHF 8 million in…
Read MoreLaxiPed Secures Innosuisse Grant to Revolutionise Foot Orthopaedics with Precision Diagnostics
LaxiPed, a Geneva-based life sciences project, has received an Innosuisse grant of CHF 679,000 to support the clinical validation of its innovative diagnostic device for foot orthopaedics. This key milestone will allow the team to take the next step toward improving diagnosis, surgical planning, and patient outcomes for conditions such as hallux valgus (bunion)—a highly…
Read MoreCHUV inaugurates its Bladder Cancer Center
Inaugurated on 1 June 2025, the Bladder Cancer Center is the eleventh interdisciplinary oncology center created at the University Hospital of Vaud (CHUV). It aims to improve the quality and safety of care by offering patients state-of-the-art treatment combining specialized surgery, innovative systemic therapies, and a rehabilitation programme. Every year in Switzerland, bladder…
Read MoreSwitzerland Innovation Parks and Microsoft Collaboration for AI-Powered Solutions
The Switzerland Innovation Parks and Microsoft have announced a collaboration to accelerate the development and deployment of AI-powered solutions across Switzerland. The collaboration aims to empower startups and SMEs by embedding cutting-edge AI capabilities into the country’s leading innovation environments. This initiative will be implemented locally through the six Switzerland Innovation Parks that…
Read MoreAtinary Technologies Gets Funding to Accelerate Antibiotics Discovery with AI
Atinary Technologies, a pioneering Swiss deeptech startup, has announced its participation in a groundbreaking project funded by AIchemy, a UK-based initiative supported by the Engineering and Physical Sciences Research Council. In partnership with the Frei Lab at the University of York, Atinary is set to transform antibiotic discovery by focusing on a promising yet underexplored…
Read MoreDePoly gets a Economic Award
DePoly gets the Swiss Economic Award 2025 in the “Deeptech / Life Science” category, with a CHF 25’000 cash prize. The award ceremony took place this Friday in Interlaken, attended by part of the Sion-based startup team and representatives from the political and economic spheres. DePoly’s innovative technology breaks down PET and polyester into…
Read MoreSwitzerland Invests CHF 666 Million to Join European Research Programmes
Fantastic news for the Swiss Health Valley and the Swiss scientific community! On 4 June 2025, the Swiss Parliament approved an additional CHF 666 million to support Switzerland’s full participation in key European research and innovation programmes — including Horizon Europe, Euratom, and Digital Europe. Switzerland must be able to participate in European…
Read MoreBrainQuant SA Revolutionizes Neurodegenerative Diseases Detection
BrainQuant SA is a Wyss Center Geneva spin-off co-founded in partnership with EPFL, University of Geneva (UNIGE), and HCK Healthcare Konnect. The new company, led by internationally recognized experts in neuroradiology, bioengineering, and digital health, is poised to transform how neurodegenerative diseases are detected. BrainQuant harnesses the power of artificial intelligence to analyze Arterial…
Read MoreUNIGE 3R Prize 2025 Awarded for Breakthrough in Kidney Cancer Research
Since 2016, the University of Geneva (UNIGE) has awarded the 3R Prize to recognize research that advances the replacement, reduction, or refinement (3R) of animal use in science. The 2025 prize was awarded on 3 June 2025 to Prof. Patrycja Nowak-Sliwinska and Dr. Daniel Benamran for developing a novel protocol to culture kidney cancer organoids…
Read MoreClaire Charmet is the New CEO of CHUV
The new CEO of CHUV took up her position on 1 June 2025. Claire Charmet is already familiar with the institution, having observed it in her role as a member of the strategic council. She has made hospital management her career for the past 15 years. Aged 42, Claire Charmet has been managing the…
Read More